Domestic bevedra-bead single anti-price again! Heng Rui and others will "go to war" Roche Anwitting face a clampdown.

Wen/Linan recently, Cinda bio-bel-babe bead sing-injection net price exposure, as the second domestic Beva beads monoanti-bio-similar drugs, the price is lower than the original research and domestic productsprice war is behind the billion-dollar market competition, and domestic giants and so on are about to "war", with the European and American market patent expiration, Amgen, Pfizer have entered the market, Roche this ace drug is afraid to hide the performance of hidden worries ..Billions of market competition, Hengrui, green leaves, etcwill "participate in the war" July 10, Shaanxi Province Public Resources Trading Center issued "on the newly approved listed drug-related publicity", which Cinda bio-bevalu beads singum singic injection, hanging net price of 1188 yuan / bottle (4ml: 100mg)Cinda bio-bel-bead singofa injection (commodity name: Dayou Tong) was approved for listing in June this year, is the second domestic Bevala beads monoimmune analogue productsthe price of this hanging network than Roche, Qilu Pharmaceuticals are currently quoted lower, once again refresh the price of bevalo-beads monoantithing drugsBeva bead monotomoine, developed by Roche, is a recombinant humanized anti-vascular endothelial growth factor (VEGF) monoantithedVEGF is an important signaling molecule in the angiogenesis process and is overexpressed in the endothelial cells of many tumorsbevazumab inhibits the conduction of PI3K-Akt/PKB and Ras-Raf-MEK-ERK signaling pathways by blocking VEGF and VEGF receptors on the surface of vascular endothelial cells, blocking the generation of new blood vessels and blood supply to the tumor, thus "starving" the tumorBeva zuma sepsis has expanded to eight solid tumor symas such as non-small cell lung cancer and glioblastoma since it was approved by the FDA in February 2004 for the treatment of metastatic colorectal cancer2010, Roche's Avastin ®, generic name: bevacizumab, was approved in China for a product called Anvitimis worth noting that before the inclusion of medical insurance, the median bid price for beifa bead sing-singular resistance was 5253 yuan per bottleafter negotiations into the national health insurance catalog, in 2017 to 1998 yuan per bottle, in 2018 further to 1934 yuan / bottle, 2019 to reduce the price of 24.92 percent, is expected to be 1500 yuan/ bottleDecember 2019, Qilu Pharmaceutical's Bevalzhu sing-it-againstinjection (commodity name: Amada) was approved as the first domestically produced bevalo-beaded monoto-retinantprice from 1266 yuan/ bottle to 1198 yuan / bottleWanlian Securities pointed out that the sharp decline in the price of Beval-Zhu-Sing- makes the market accessibility greatly improved, in recent years, the original research varieties sales in the domestic market to maintain an average annual growth rate of more than 40%, is expected to reach 2019 sales of more than 3.2 billion yuanand with the subsequent more cost-effective domestic generic drugs on the market, the drug market space will be further opened Sales revenue in China's beifa-zuma biosimilar drug market is expected to grow at a CAGR of 343.5 percent from 2019, with the market size of about 6.4 billion yuan in 2023 and 9.9 billion yuan by 2030, according to the Frostshali report it is understood that in addition to the domestic enterprises in Qilu, Cinda's Bevalzhu sing-injection has been approved for listing, Hengrui Pharmaceuticals, Green Leaf Pharmaceuticals, Bai Otai have reported production, the third domestic Bevala beads monoanti-bio-like drugs do not know who will flower? However, the subsequent impact of price reduction policies, such as the national linkage of the lowest price, generic drug companies pricing is limited, which will also become a test of the overall strength of enterprises a level chart source: Wanlian Securities, in addition, Dongyi Pharmaceuticals, Jiahe Bio, Fuhong Hanxuan, Zhengda Tianqing, Hualan Gene, Shenzhou Cell and Anke Bio equivalent products are currently in Phase 3 clinical trials Insight database, there are currently 16 clinical trials, 12 approved clinical trials, 4 clinical applications in the clinical application, the domestic competition is fierce Anwitin, one of the Roche aces, faces a "clamping" of Avastin, Rituxan and Herceptin, known as Roche's super-heavyweight oncology "troika" and a long-term driver of its performance , Avetin's global sales for 2018 and 2019 reached 6.85 billion and 7.07 billion Swiss francs, respectively the drug sales core is still in Europe and the United States, the United States and the European Union in 2019 sales of 30.19 billion, 1,794 million Swiss francs, respectively source: Roche's 2019 earnings report revealed that with the expiration of patents and the increasing number of biosimilars approved and commercialized, Heceptin and Merofa began to fall in 2019, with only Anvitin still growing Avetin's 2019 regional results, anavetin, while sales have not fallen, but also face a potential crisis its patents in the U.S and the European Union expire in 2019 and 2020, respectively , Amgen/Elgen's Mvasi and Pfizer's Zirabev have been approved for sale in the United States and the European Union, both of which are biosimilars of bevalo-singyan , Mvasi and Zirabev were commercialized in the United States in July 2019 and January 2020, respectively pricing, Amgen and Aljian have said that Mvasi's wholesale price is 15 per cent lower than the original in addition, some varieties abroad are in the listing application, as well as clinical research at different stages with the disappearance of the patent dividend period, competition in the European and American markets for generic products, as well as the Chinese market biosimilars concentrated on the market, the industry is expected to 2020 Roche Anvetin global performance will show a downward trend Note: The relevant information refers to the 2019 financial results of Wanlian Securities and Roche.